Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz Sues FDA For Inaction On Omnitrope NDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Lawsuit seeks a court declaration that the 505(b)(2) pathway “can be used for protein-based biologic drugs regulated under Section 505 of the FD&C Act.”

You may also be interested in...



Amphastar Seeks Court Order Requiring FDA To Approve Its Enoxaparin ANDA

Amphastar’s initial lawsuit against FDA achieved its stated goal: the agency released two shipments of raw heparin material the company is to use in producing generic Lovenox (enoxaparin).

Amphastar Seeks Court Order Requiring FDA To Approve Its Enoxaparin ANDA

Amphastar’s initial lawsuit against FDA achieved its stated goal: the agency released two shipments of raw heparin material the company is to use in producing generic Lovenox (enoxaparin).

FDA Must Take Action On Sandoz' Omnitrope Application, U.S. District Court says

The agency sees three options – appeal, approve or put to a hearing – following the decision which found that FDA had failed to meet its statutory timetable.

Related Content

Topics

UsernamePublicRestriction

Register

OM013057

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel